サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1788312

組み換えタンパク質製造サービスの世界市場

Recombinant Proteins Manufacturing Services

出版日
ページ情報
英文 175 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.53円
組み換えタンパク質製造サービスの世界市場
出版日: 2025年08月12日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 175 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

組み換えタンパク質製造サービスの世界市場は2030年までに153億米ドルに到達

2024年に52億米ドルと推定される組み換えタンパク質製造サービスの世界市場は、2024年から2030年にかけてCAGR 19.7%で成長し、2030年には153億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである商業生産サービスは、CAGR 21.2%を記録し、分析期間終了までに108億米ドルに達すると予測されます。前臨床・臨床サービス分野の成長率は、分析期間中CAGR16.5％と推定されます。

米国市場は14億米ドルと推定・中国はCAGR18.6%で成長予測

米国の組み換えタンパク質製造サービス市場は2024年に14億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに23億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは18.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ18.3％と16.9％と予測されています。欧州では、ドイツがCAGR約14.3%で成長すると予測されています。

世界の組み換えタンパク質製造サービス市場- 主要動向と促進要因のまとめ

組換えタンパク質製造のアウトソーシングが戦略上不可欠になりつつあるのはなぜか？

組換えタンパク質製造サービスは、製薬会社やバイオテクノロジー企業が専門的な製造受託機関（CMO）や開発・製造受託機関（CDMO）への製造委託を増やすにつれて、大きな支持を得ています。大規模なタンパク質発現、精製、規制遵守に伴う複雑性から、アウトソーシングはコストの最適化と製品開発の迅速化を目指す企業にとって魅力的な選択肢となっています。モノクローナル抗体、融合タンパク質、サイトカインなどの生物学的製剤のパイプラインが増加しているため、高品質の組み換えタンパク質製造サービスへの需要がさらに高まっています。さらに、新興企業や中堅バイオテクノロジー企業は、自社での生産能力を持たないことが多いため、CMOとの提携を活用して新規治療薬を効率的に市場に投入しています。バイオ医薬品産業が拡大するにつれ、組み換えタンパク質製造サービスは、スケーラブルでコスト効率に優れ、規制に準拠した製造を保証する上で重要な役割を果たしています。

技術革新は組換えタンパク質製造サービスをどのように強化しているか？

バイオプロセス技術の進歩は、組換えタンパク質製造の効率とスケーラビリティを大幅に改善しました。シングルユース・バイオリアクターと灌流システムは、コンタミネーションのリスクを低減し、プロセスの柔軟性を高めることによって、タンパク質生産に革命をもたらしました。哺乳類細胞、昆虫細胞、微生物プラットフォームを含む高収率発現システムの使用は、構造忠実性と生物活性を維持しながら、タンパク質生産をさらに最適化しました。AI主導のプロセス最適化とリアルタイム分析により、予測的品質管理が可能になり、バッチ間のばらつきが減少し、全体的な製造効率が向上しました。さらに、上流工程と下流工程の自動化とロボット化によって、作業が合理化され、手作業による介入が減り、再現性が向上しています。こうした技術的進歩は組換えタンパク質製造サービスに変革をもたらし、より迅速で信頼性が高く、コスト効率の高い生産を可能にしています。

組換えタンパク質製造サービスの需要を牽引している市場動向とは？

生物製剤と個別化医療が重視されるようになり、組換えタンパク質の受託製造サービスへの依存度が高まっています。バイオ医薬品企業は、規制上の課題を克服し、製造ワークフローを最適化するためにCMO/CDMOの専門知識を活用し、市場投入までのスピード戦略を優先しています。バイオシミラーやバイオベッターの開発が活発化していることも、規制遵守やプロセスの拡張性を確保できる専門的な製造サービスへの需要をさらに高めています。さらに、連続製造とモジュール式生産設備の採用が増加しているため、柔軟で効率的なタンパク質生産が可能になっています。細胞培養培地や治療用途に組換えタンパク質を必要とする細胞治療や遺伝子治療研究の拡大も、市場の成長に寄与しています。製薬会社が費用対効果が高く拡張性のある製造ソリューションを求める中、組み換えタンパク質製造サービス市場は急速に拡大すると予想されます。

組み換えタンパク質製造サービス市場の主な成長促進要因は？

世界の組み換えタンパク質製造サービス市場の成長は、生物製剤に対する需要の増加、バイオプロセス技術の進歩、医薬品製造におけるアウトソーシングの普及の高まりなど、いくつかの要因によってもたらされます。発現システム、精製、法規制遵守に関する専門知識を必要とする組換えタンパク質製造の複雑化が、製造受託パートナーシップの需要をさらに高めています。さらに、バイオシミラー医薬品や個別化医薬品のパイプラインの拡大が、スケーラブルでコスト効率の高いタンパク質生産サービスの必要性を高めています。GMP認定製造施設に対する投資の増加は、AI主導のバイオプロセス最適化の進歩と相まって、市場の拡大をさらに後押ししています。バイオマニュファクチャリングにおける継続的な技術革新により、組み換えタンパク質製造サービス市場は、生物学的製剤の開発と商業化の将来において極めて重要な役割を果たすと予想されます。

セグメント

サービス（商業生産サービス、前臨床・臨床サービス）、宿主細胞（哺乳類細胞、細菌細胞、酵母・真菌、昆虫細胞、その他の宿主細胞）、エンドユーザー（製薬・バイオテクノロジー企業エンドユーザー、学術・研究機関エンドユーザー）

調査対象企業の例

  • ACROBiosystems
  • Biointron Biological Inc.
  • Biomatik Corporation
  • Bio-Rad Laboratories, Inc.
  • Biorbyt Ltd
  • Creative BioMart
  • CUSABIO Technology LLC
  • Dundee Cell Products Ltd
  • Echo Biosystems
  • GenScript Biotech Corporation
  • IBA Lifesciences
  • Jena Bioscience GmbH
  • KACTUS Biosystems
  • Novoprotein Scientific Inc.
  • Q-bios GmbH
  • R&D Systems（Bio-Techne）
  • Revvity（Germany）GmbH
  • Syngene International Ltd
  • Ventria Bioscience
  • WuXi Biologics

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP32766

Global Recombinant Proteins Manufacturing Services Market to Reach US$15.3 Billion by 2030

The global market for Recombinant Proteins Manufacturing Services estimated at US$5.2 Billion in the year 2024, is expected to reach US$15.3 Billion by 2030, growing at a CAGR of 19.7% over the analysis period 2024-2030. Commercial Production Services, one of the segments analyzed in the report, is expected to record a 21.2% CAGR and reach US$10.8 Billion by the end of the analysis period. Growth in the Pre-Clinical & Clinical Services segment is estimated at 16.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 18.6% CAGR

The Recombinant Proteins Manufacturing Services market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.3 Billion by the year 2030 trailing a CAGR of 18.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 18.3% and 16.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.3% CAGR.

Global Recombinant Proteins Manufacturing Services Market - Key Trends & Drivers Summarized

Why Is Outsourcing Recombinant Protein Manufacturing Becoming a Strategic Imperative?

Recombinant protein manufacturing services have gained significant traction as pharmaceutical and biotech companies increasingly outsource production to specialized contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs). The complexities involved in large-scale protein expression, purification, and regulatory compliance make outsourcing an attractive option for companies looking to optimize costs and accelerate product development. The growing pipeline of biologic drugs, including monoclonal antibodies, fusion proteins, and cytokines, has further increased demand for high-quality recombinant protein manufacturing services. Additionally, startups and mid-sized biotech firms, which often lack in-house production capabilities, are leveraging CMO partnerships to bring novel therapies to market efficiently. As the biopharmaceutical industry expands, recombinant protein manufacturing services are playing a critical role in ensuring scalable, cost-effective, and regulatory-compliant production.

How Are Technological Innovations Enhancing Recombinant Protein Manufacturing Services?

The advancement of bioprocessing technologies has significantly improved the efficiency and scalability of recombinant protein manufacturing. Single-use bioreactors and perfusion systems have revolutionized protein production by reducing contamination risks and increasing process flexibility. The use of high-yield expression systems, including mammalian cells, insect cells, and microbial platforms, has further optimized protein production while maintaining structural fidelity and bioactivity. AI-driven process optimization and real-time analytics have enabled predictive quality control, reducing batch-to-batch variability and improving overall manufacturing efficiency. Moreover, automation and robotics in upstream and downstream processing are streamlining operations, reducing manual intervention, and enhancing reproducibility. These technological advancements are transforming recombinant protein manufacturing services, enabling faster, more reliable, and cost-effective production.

What Market Trends Are Driving the Demand for Recombinant Protein Manufacturing Services?

The growing emphasis on biologics and personalized medicine has led to an increasing reliance on contract manufacturing services for recombinant proteins. Biopharmaceutical companies are prioritizing speed-to-market strategies, leveraging CMO/CDMO expertise to navigate regulatory challenges and optimize production workflows. The rising development of biosimilars and biobetters has further fueled demand for specialized manufacturing services that can ensure regulatory compliance and process scalability. Additionally, the increasing adoption of continuous manufacturing and modular production facilities is enabling flexible and efficient protein production. The expansion of cell therapy and gene therapy research, which requires recombinant proteins for cell culture media and therapeutic applications, has also contributed to market growth. As pharmaceutical companies seek cost-effective and scalable manufacturing solutions, the recombinant protein manufacturing services market is expected to expand rapidly.

What Are the Key Growth Drivers of the Recombinant Proteins Manufacturing Services Market?

The growth in the global recombinant protein manufacturing services market is driven by several factors, including increasing demand for biologics, advances in bioprocessing technologies, and the rising prevalence of outsourcing in pharmaceutical manufacturing. The growing complexity of recombinant protein production, requiring specialized expertise in expression systems, purification, and regulatory compliance, has further fueled demand for contract manufacturing partnerships. Additionally, the expansion of biosimilar and personalized medicine pipelines is driving the need for scalable and cost-efficient protein production services. The increasing investments in GMP-certified manufacturing facilities, coupled with advancements in AI-driven bioprocess optimization, are further supporting market expansion. With continued innovation in biomanufacturing, the recombinant protein manufacturing services market is expected to play a pivotal role in the future of biologic drug development and commercialization.

SCOPE OF STUDY:

The report analyzes the Recombinant Proteins Manufacturing Services market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Service (Commercial Production Services, Pre-Clinical & Clinical Services); Host Cell (Mammalian Cells, Bacterial Cells, Yeast & Fungi, Insect Cells, Other Host Cells); End-Use (Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

  • ACROBiosystems
  • Biointron Biological Inc.
  • Biomatik Corporation
  • Bio-Rad Laboratories, Inc.
  • Biorbyt Ltd
  • Creative BioMart
  • CUSABIO Technology LLC
  • Dundee Cell Products Ltd
  • Echo Biosystems
  • GenScript Biotech Corporation
  • IBA Lifesciences
  • Jena Bioscience GmbH
  • KACTUS Biosystems
  • Novoprotein Scientific Inc.
  • Q-bios GmbH
  • R&D Systems (Bio-Techne)
  • Revvity (Germany) GmbH
  • Syngene International Ltd
  • Ventria Bioscience
  • WuXi Biologics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Recombinant Proteins Manufacturing Services - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Biopharmaceutical Outsourcing Trend Propels Demand for Contract-Based Recombinant Protein Manufacturing
    • Rising Complexity of Protein Therapeutics Strengthens Business Case for Specialized Manufacturing Partners
    • Expansion of Personalized and Rare Disease Therapies Throws the Spotlight on Small-Batch Manufacturing Services
    • Rapid Development of Cell-Based Therapies Spurs Custom Recombinant Protein Supply Contracts
    • Increased Regulatory Scrutiny Promotes Outsourcing to GMP-Compliant Manufacturing Facilities
    • Growth in Synthetic Biology and Protein Engineering Drives Demand for Design-to-Delivery CDMO Capabilities
    • Wider Adoption of Continuous Manufacturing Technologies Enhances Scalability and Reduces Costs
    • Expansion of Multi-Expression System Capabilities Improves Service Flexibility for Biotech Clients
    • Innovation in Downstream Processing Enhances Yield and Drives Competitive Differentiation
    • Demand for Accelerated Drug Development Timelines Strengthens Need for Agile and Responsive CDMOs
    • Rising Venture Capital Funding for Startups Spurs Partnerships with Protein Manufacturing Specialists
    • Cross-Sector Collaboration in Diagnostics and Therapeutics Expands Protein Use Cases and Manufacturing Demand
    • Emphasis on Quality-by-Design and PAT Integration Elevates Process Optimization Standards
    • Emergence of Cloud-Based Data Sharing and Monitoring Enhances Transparency and Compliance
    • Globalization of Clinical Trials Supports Distributed and Regionally Adaptive Manufacturing Models
    • Requirement for Lot-to-Lot Consistency Fuels Reliance on Expert CDMOs for Regulatory Submissions
    • Growth of Companion Diagnostics and Biomarker Development Expands Recombinant Protein Applications
    • Development of Proprietary Protein Platforms Spurs Licensing Partnerships with CDMOs
    • Use of Disposable Bioreactor Systems Streamlines Project Turnaround and Reduces Contamination Risk
    • Long-Term Strategic Manufacturing Agreements Between Pharma and CDMOs Create Market Stability
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recombinant Proteins Manufacturing Services Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Recombinant Proteins Manufacturing Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Commercial Production Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Commercial Production Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Pre-Clinical & Clinical Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Pre-Clinical & Clinical Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Mammalian Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Mammalian Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Bacterial Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Bacterial Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Yeast & Fungi by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Yeast & Fungi by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Insect Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Insect Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Other Host Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Other Host Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Recombinant Proteins Manufacturing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 22: USA Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by Service - Commercial Production Services and Pre-Clinical & Clinical Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for Recombinant Proteins Manufacturing Services by Service - Percentage Breakdown of Value Sales for Commercial Production Services and Pre-Clinical & Clinical Services for the Years 2025 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by Host Cell - Mammalian Cells, Bacterial Cells, Yeast & Fungi, Insect Cells and Other Host Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Recombinant Proteins Manufacturing Services by Host Cell - Percentage Breakdown of Value Sales for Mammalian Cells, Bacterial Cells, Yeast & Fungi, Insect Cells and Other Host Cells for the Years 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by End-Use - Pharma & Biotech Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Recombinant Proteins Manufacturing Services by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
  • CANADA
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by Service - Commercial Production Services and Pre-Clinical & Clinical Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Canada 6-Year Perspective for Recombinant Proteins Manufacturing Services by Service - Percentage Breakdown of Value Sales for Commercial Production Services and Pre-Clinical & Clinical Services for the Years 2025 & 2030
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by Host Cell - Mammalian Cells, Bacterial Cells, Yeast & Fungi, Insect Cells and Other Host Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for Recombinant Proteins Manufacturing Services by Host Cell - Percentage Breakdown of Value Sales for Mammalian Cells, Bacterial Cells, Yeast & Fungi, Insect Cells and Other Host Cells for the Years 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by End-Use - Pharma & Biotech Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for Recombinant Proteins Manufacturing Services by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
  • JAPAN
    • Recombinant Proteins Manufacturing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 34: Japan Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by Service - Commercial Production Services and Pre-Clinical & Clinical Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Japan 6-Year Perspective for Recombinant Proteins Manufacturing Services by Service - Percentage Breakdown of Value Sales for Commercial Production Services and Pre-Clinical & Clinical Services for the Years 2025 & 2030
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by Host Cell - Mammalian Cells, Bacterial Cells, Yeast & Fungi, Insect Cells and Other Host Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for Recombinant Proteins Manufacturing Services by Host Cell - Percentage Breakdown of Value Sales for Mammalian Cells, Bacterial Cells, Yeast & Fungi, Insect Cells and Other Host Cells for the Years 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by End-Use - Pharma & Biotech Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for Recombinant Proteins Manufacturing Services by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
  • CHINA
    • Recombinant Proteins Manufacturing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 40: China Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by Service - Commercial Production Services and Pre-Clinical & Clinical Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: China 6-Year Perspective for Recombinant Proteins Manufacturing Services by Service - Percentage Breakdown of Value Sales for Commercial Production Services and Pre-Clinical & Clinical Services for the Years 2025 & 2030
    • TABLE 42: China Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by Host Cell - Mammalian Cells, Bacterial Cells, Yeast & Fungi, Insect Cells and Other Host Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for Recombinant Proteins Manufacturing Services by Host Cell - Percentage Breakdown of Value Sales for Mammalian Cells, Bacterial Cells, Yeast & Fungi, Insect Cells and Other Host Cells for the Years 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by End-Use - Pharma & Biotech Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for Recombinant Proteins Manufacturing Services by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
  • EUROPE
    • Recombinant Proteins Manufacturing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 46: Europe Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 47: Europe 6-Year Perspective for Recombinant Proteins Manufacturing Services by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by Service - Commercial Production Services and Pre-Clinical & Clinical Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for Recombinant Proteins Manufacturing Services by Service - Percentage Breakdown of Value Sales for Commercial Production Services and Pre-Clinical & Clinical Services for the Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by Host Cell - Mammalian Cells, Bacterial Cells, Yeast & Fungi, Insect Cells and Other Host Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Recombinant Proteins Manufacturing Services by Host Cell - Percentage Breakdown of Value Sales for Mammalian Cells, Bacterial Cells, Yeast & Fungi, Insect Cells and Other Host Cells for the Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by End-Use - Pharma & Biotech Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Recombinant Proteins Manufacturing Services by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
  • FRANCE
    • Recombinant Proteins Manufacturing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 54: France Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by Service - Commercial Production Services and Pre-Clinical & Clinical Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: France 6-Year Perspective for Recombinant Proteins Manufacturing Services by Service - Percentage Breakdown of Value Sales for Commercial Production Services and Pre-Clinical & Clinical Services for the Years 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by Host Cell - Mammalian Cells, Bacterial Cells, Yeast & Fungi, Insect Cells and Other Host Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for Recombinant Proteins Manufacturing Services by Host Cell - Percentage Breakdown of Value Sales for Mammalian Cells, Bacterial Cells, Yeast & Fungi, Insect Cells and Other Host Cells for the Years 2025 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by End-Use - Pharma & Biotech Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Recombinant Proteins Manufacturing Services by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
  • GERMANY
    • Recombinant Proteins Manufacturing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 60: Germany Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by Service - Commercial Production Services and Pre-Clinical & Clinical Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Germany 6-Year Perspective for Recombinant Proteins Manufacturing Services by Service - Percentage Breakdown of Value Sales for Commercial Production Services and Pre-Clinical & Clinical Services for the Years 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by Host Cell - Mammalian Cells, Bacterial Cells, Yeast & Fungi, Insect Cells and Other Host Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for Recombinant Proteins Manufacturing Services by Host Cell - Percentage Breakdown of Value Sales for Mammalian Cells, Bacterial Cells, Yeast & Fungi, Insect Cells and Other Host Cells for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by End-Use - Pharma & Biotech Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Recombinant Proteins Manufacturing Services by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
  • ITALY
    • TABLE 66: Italy Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by Service - Commercial Production Services and Pre-Clinical & Clinical Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Italy 6-Year Perspective for Recombinant Proteins Manufacturing Services by Service - Percentage Breakdown of Value Sales for Commercial Production Services and Pre-Clinical & Clinical Services for the Years 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by Host Cell - Mammalian Cells, Bacterial Cells, Yeast & Fungi, Insect Cells and Other Host Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for Recombinant Proteins Manufacturing Services by Host Cell - Percentage Breakdown of Value Sales for Mammalian Cells, Bacterial Cells, Yeast & Fungi, Insect Cells and Other Host Cells for the Years 2025 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by End-Use - Pharma & Biotech Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for Recombinant Proteins Manufacturing Services by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
  • UNITED KINGDOM
    • Recombinant Proteins Manufacturing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 72: UK Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by Service - Commercial Production Services and Pre-Clinical & Clinical Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: UK 6-Year Perspective for Recombinant Proteins Manufacturing Services by Service - Percentage Breakdown of Value Sales for Commercial Production Services and Pre-Clinical & Clinical Services for the Years 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by Host Cell - Mammalian Cells, Bacterial Cells, Yeast & Fungi, Insect Cells and Other Host Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for Recombinant Proteins Manufacturing Services by Host Cell - Percentage Breakdown of Value Sales for Mammalian Cells, Bacterial Cells, Yeast & Fungi, Insect Cells and Other Host Cells for the Years 2025 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by End-Use - Pharma & Biotech Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for Recombinant Proteins Manufacturing Services by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by Service - Commercial Production Services and Pre-Clinical & Clinical Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Rest of Europe 6-Year Perspective for Recombinant Proteins Manufacturing Services by Service - Percentage Breakdown of Value Sales for Commercial Production Services and Pre-Clinical & Clinical Services for the Years 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by Host Cell - Mammalian Cells, Bacterial Cells, Yeast & Fungi, Insect Cells and Other Host Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for Recombinant Proteins Manufacturing Services by Host Cell - Percentage Breakdown of Value Sales for Mammalian Cells, Bacterial Cells, Yeast & Fungi, Insect Cells and Other Host Cells for the Years 2025 & 2030
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by End-Use - Pharma & Biotech Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for Recombinant Proteins Manufacturing Services by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Recombinant Proteins Manufacturing Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by Service - Commercial Production Services and Pre-Clinical & Clinical Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Asia-Pacific 6-Year Perspective for Recombinant Proteins Manufacturing Services by Service - Percentage Breakdown of Value Sales for Commercial Production Services and Pre-Clinical & Clinical Services for the Years 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by Host Cell - Mammalian Cells, Bacterial Cells, Yeast & Fungi, Insect Cells and Other Host Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for Recombinant Proteins Manufacturing Services by Host Cell - Percentage Breakdown of Value Sales for Mammalian Cells, Bacterial Cells, Yeast & Fungi, Insect Cells and Other Host Cells for the Years 2025 & 2030
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by End-Use - Pharma & Biotech Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for Recombinant Proteins Manufacturing Services by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by Service - Commercial Production Services and Pre-Clinical & Clinical Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of World 6-Year Perspective for Recombinant Proteins Manufacturing Services by Service - Percentage Breakdown of Value Sales for Commercial Production Services and Pre-Clinical & Clinical Services for the Years 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by Host Cell - Mammalian Cells, Bacterial Cells, Yeast & Fungi, Insect Cells and Other Host Cells - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for Recombinant Proteins Manufacturing Services by Host Cell - Percentage Breakdown of Value Sales for Mammalian Cells, Bacterial Cells, Yeast & Fungi, Insect Cells and Other Host Cells for the Years 2025 & 2030
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Recombinant Proteins Manufacturing Services by End-Use - Pharma & Biotech Companies End-Use and Academic & Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for Recombinant Proteins Manufacturing Services by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use and Academic & Research Institutes End-Use for the Years 2025 & 2030

IV. COMPETITION